Somagenetix is pioneering gene therapy for phagocyte disorders, focusing on innovative therapies that provide one-time treatments with targeted activity
Somagenetix is pioneering gene therapy for phagocyte disorders, focusing on innovative therapies that provide one-time treatments with targeted activity. Their lead product, SGX-001, is in clinical trials for Chronic Granulomatous Disease.